Kura Oncology (NASDAQ:KURA) Shares Gap Down – Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA) gapped down before the market opened on Friday . The stock had previously closed at $17.77, but opened at $16.77. Kura Oncology shares last traded at $17.24, with a volume of 58,885 shares trading hands.

Wall Street Analysts Forecast Growth

KURA has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Wedbush reiterated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. UBS Group initiated coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The company has a market cap of $1.35 billion, a P/E ratio of -7.49 and a beta of 0.86. The stock has a fifty day moving average price of $18.78 and a two-hundred day moving average price of $20.00.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. Kura Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts forecast that Kura Oncology, Inc. will post -2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $507,000. Assenagon Asset Management S.A. increased its holdings in shares of Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC grew its holdings in shares of Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.